GATA4 transgenic mice as an in vivo model of congenital heart disease

Han,Hua; Chen,Yu; Liu,Gang; Han,Zengqiang; Zhao,Zhou; Tang,Yin

doi:10.3892/ijmm.2015.2178

GATA4 transgenic mice as an in vivo model of congenital heart disease

Authors:
- Hua Han
- Yu Chen
- Gang Liu
- Zengqiang Han
- Zhou Zhao
- Yin Tang
View Affiliations

Affiliations: Department of Cardiovascular Surgery, Peking University People's Hospital, Beijing 100044, P.R. China
Published online on: April 9, 2015 https://doi.org/10.3892/ijmm.2015.2178
Pages: 1545-1553
Copyright: © Han et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Our previous study indicated that 8 patients from a family with a history of congenital heart disease had simple atrial septal defect (ASD) and carried the same mutation at codon 310 in the GATA4 gene. In the present study, to identify the functional defects caused by this mutation in an in vivo model, the transgene DNA constructs were microinjected into mice to generate a transgenic mouse model. The mice were genotyped using PCR and DNA sequencing. Protein expression was measured by western blot analysis. qPCR was used to determine the copy number of the transgenes. The heart tissue was fixed and sectioned by conventional procedures. The Vevo 2000 system was used to perform echocardiography on the mice. The expression of GATA4 target genes was measured using the real-time PCR system. The incidence of ASD in the heterozygous transgenic mice was found to be greater than that in the wild-type control mice (P<0.05). In addition, the expression of α-myosin heavy chain (α-MHC) in the heart tissues from the homozygous mice was lower than that in the heart tissues from their wild-type littermates (P<0.05). In conclusion, these results suggest that the introduction of GATA4 M310V negatively affects the normal expression of α-MHC. In accordance with previous findings on GATA4 mutation screening and in vitro experiments, this study confirms that GATA4 M310V mutation may lead to the development of the congenital heart defect, ASD.

View Figures

View References

1	Bentham J and Bhattacharya S: Genetic mechanisms controlling cardiovascular development. Ann NY Acad Sci. 1123:10–19. 2008. View Article : Google Scholar : PubMed/NCBI
2	Molkentin JD, Lin Q, Duncan SA and Olson EN: Requirement of the transcription factor GATA4 for heart tube formation and ventral morphogenesis. Genes Dev. 11:1061–1072. 1997. View Article : Google Scholar : PubMed/NCBI
3	Brunskill EW, Witte DP, Yutzey KE and Potter SS: Novel cell lines promote the discovery of genes involved in early heart development. Dev Biol. 235:507–520. 2001. View Article : Google Scholar : PubMed/NCBI
4	Temsah R and Nemer M: GATA factors and transcriptional regulation of cardiac natriuretic peptide genes. Regul Pept. 128:177–185. 2005. View Article : Google Scholar : PubMed/NCBI
5	Sarkozy A, Conti E, Neri C, D’Agostino R, Digilio MC, Esposito G, Toscano A, Marino B, Pizzuti A and Dallapiccola B: Spectrum of atrial septal defects associated with mutations of NKX2.5 and GATA4 transcription factors. J Med Genet. 42:e162005. View Article : Google Scholar : PubMed/NCBI
6	Garg V, Kathiriya IS, Barnes R, et al: GATA4 mutations cause human congenital heart defects and reveal an interaction with TBX5. Nature. 424:443–447. 2003. View Article : Google Scholar : PubMed/NCBI
7	Christoforou N, Chellappan M, Adler AF, Kirkton RD, Wu T, Addis RC, Bursac N and Leong KW: Transcription factors MYOCD, SRF, Mesp1 and SMARCD3 enhance the cardio-inducing effect of GATA4, TBX5, and MEF2C during direct cellular reprogramming. PLoS One. 8:e635772013. View Article : Google Scholar : PubMed/NCBI
8	Dodou E, Verzi MP, Anderson JP, Xu SM and Black BL: Mef2c is a direct transcriptional target of ISL1 and GATA factors in the anterior heart field during mouse embryonic development. Development. 131:3931–3942. 2004. View Article : Google Scholar : PubMed/NCBI
9	Chen Y, Han ZQ, Yan WD, Tang CZ, Xie JY, Chen H and Hu DY: A novel mutation in GATA4 gene associated with dominant inherited familial atrial septal defect. J Thorac Cardiovasc Surg. 140:684–687. 2010. View Article : Google Scholar : PubMed/NCBI
10	Xiang R, Fan LL, Huang H, Cao BB, Li XP, Peng DQ and Xia K: A novel mutation of GATA4 (K319E) is responsible for familial atrial septal defect and pulmonary valve stenosis. Gene. 534:320–323. 2014. View Article : Google Scholar : PubMed/NCBI
11	Garg V, Kathiriya IS, Barnes R, Schluterman MK, King IN, Butler CA, Rothrock CR, Eapen RS, Hirayama-Yamada K, Joo K, Matsuoka R, Cohen JC and Srivastava D: GATA4 mutations cause human congenital heart defects and reveal an interaction with TBX5. Nature. 424:443–447. 2003. View Article : Google Scholar : PubMed/NCBI
12	Maitra M, Schluterman MK, Nichols HA, Richardson JA, Lo CW, Srivastava D and Garg V: Interaction of Gata4 and Gata6 with Tbx5 is critical for normal cardiac development. Dev Biol. 326:368–377. 2009. View Article : Google Scholar :
13	Laforest B and Nemer M: GATA5 interacts with GATA4 and GATA6 in outflow tract development. Dev Biol. 358:368–378. 2011. View Article : Google Scholar : PubMed/NCBI
14	Rajagopal SK, Ma Q, Obler D, et al: Spectrum of heart disease associated with murine and human GATA4 mutation. J Mol Cell Cardiol. 43:677–685. 2007. View Article : Google Scholar : PubMed/NCBI
15	Misra C, Sachan N, McNally CR, Koenig SN, Nichols HA, Guggilam A, Lucchesi PA, Pu WT, Srivastava D and Garg V: Congenital heart disease-causing Gata4 mutation displays functional deficits in vivo. PLoS Genet. 8:e10026902012. View Article : Google Scholar : PubMed/NCBI
16	Tang Y, Han Z, Han H and Chen Y: Mechanism involved in the familial atrial septal defects caused by GATA-4 M310V single gene mutation. China Circ J. 3:211–214. 2013.In Chinese.
17	Ballester M, Castelló A, Ibáñez E, Sánchez A and Folch JM: Real-time quantitative PCR-based system for determining transgene copy number in transgenic animals. Biotechniques. 37:610–613. 2004.PubMed/NCBI
18	Nemer G, Fadlalah F, Usta J, Nemer M, Dbaibo G, Obeid M and Bitar F: A novel mutation in the GATA4 gene in patients with Tetralogy of Fallot. Hum Mutat. 27:293–294. 2006. View Article : Google Scholar : PubMed/NCBI
19	Zeisberg EM, Ma Q, Juraszek AL, Moses K, Schwartz RJ, Izumo S and Pu WT: Morphogenesis of the right ventricle requires myocardial expression of Gata4. J Clin Invest. 115:1522–1531. 2005. View Article : Google Scholar : PubMed/NCBI
20	Pu WT, Ishiwata T, Juraszek AL, Ma Q and Izumo S: GATA4 is a dosage-sensitive regulator of cardiac morphogenesis. Dev Biol. 275:235–244. 2004. View Article : Google Scholar : PubMed/NCBI
21	McBride K and Nemer M: Regulation of the ANF and BNP promoters by GATA factors: Lessons learned for cardiac transcription. Can J Physiol Pharmacol. 79:673–681. 2001. View Article : Google Scholar : PubMed/NCBI
22	Molkentin JD, Kalvakolanu DV and Markham BE: Transcription factor GATA-4 regulates cardiac muscle-specific expression of the alpha-myosin heavy-chain gene. Mol Cell Biol. 14:4947–4957. 1994.PubMed/NCBI
23	Morin S, Charron F, Robitaille L and Nemer M: GATA-dependent recruitment of MEF2 proteins to target promoters. EMBO J. 19:2046–2055. 2000. View Article : Google Scholar : PubMed/NCBI
24	Ip HS, Wilson DB, Heikinheimo M, Tang Z, Ting CN, Simon MC, Leiden JM and Parmacek MS: The GATA-4 transcription factor transactivates the cardiac muscle-specific troponin C promoter-enhancer in nonmuscle cells. Mol Cell Biol. 14:7517–7526. 1994.PubMed/NCBI
25	Zhao R, Watt AJ, Battle MA, Li J, Bondow BJ and Duncan SA: Loss of both GATA4 and GATA6 blocks cardiac myocyte differentiation and results in acardia in mice. Dev Biol. 317:614–619. 2008. View Article : Google Scholar : PubMed/NCBI
26	Jay PY, Harris BS, Maguire CT, Buerger A, Wakimoto H, Tanaka M, Kupershmidt S, Roden DM, Schultheiss TM, O’Brien TX, Gourdie RG, Berul CI and Izumo S: Nkx2-5 mutation causes anatomic hypoplasia of the cardiac conduction system. J Clin Invest. 113:1130–1137. 2004. View Article : Google Scholar : PubMed/NCBI
27	Terada R, Warren S, Lu JT, Chien KR, Wessels A and Kasahara H: Ablation of Nkx2-5 at mid-embryonic stage results in premature lethality and cardiac malformation. Cardiovasc Res. 91:289–299. 2011. View Article : Google Scholar : PubMed/NCBI
28	Takeda M, Briggs LE, Wakimoto H, Marks MH, Warren SA, Lu JT, Weinberg EO, Robertson KD, Chien KR and Kasahara H: Slow progressive conduction and contraction defects in loss of Nkx2-5 mice after cardiomyocyte terminal differentiation. Lab Invest. 89:983–993. 2009. View Article : Google Scholar : PubMed/NCBI
29	Schlesinger J, Schueler M, Grunert M, Fischer JJ, Zhang Q, Krueger T, Lange M, Tönjes M, Dunkel I and Sperling SR: The cardiac transcription network modulated by Gata4, Mef2a, Nkx2.5, Srf, histone modifications, and microRNAs. PLoS Genet. 7. pp. e10013132011, View Article : Google Scholar
30	Yamagishi H, Yamagishi C, Nakagawa O, Harvey RP, Olson EN and Srivastava D: The combinatorial activities of Nkx2.5 and dHAND are essential for cardiac ventricle formation. Dev Biol. 239:190–203. 2001. View Article : Google Scholar
31	Bruneau BG, Nemer G, Schmitt JP, Charron F, Robitaille L, Caron S, Conner DA, Gessler M, Nemer M, Seidman CE and Seidman JG: A murine model of Holt-Oram syndrome defines roles of the T-box transcription factor Tbx5 in cardiogenesis and disease. Cell. 106:709–721. 2001. View Article : Google Scholar : PubMed/NCBI